18+

 

Number №2, 2024 - page 81-88

Evaluation of the results of a comparative study of the effectiveness and safety of the use of Phosphalit® complex in patients with phosphate urolithiasis DOI: 10.29188/2222-8543-2024-17-2-81-88

For citation: Neymark B.A., Nashivochnikova N.A., Smernitsky A.M., Melnik M.A., Tupyakova S.G. Evaluation of the results of a comparative study of the effectiveness and safety of the use of Phosphalit® complex in patients with phosphate urolithiasis. Experimental and Clinical Urology 2024;17(2):81-88; https://doi.org/10.29188/2222-8543-2024-17-2-81-88
Neymark B.A., Nashivochnikova N.A., Smernitsky A.M., Melnik M.A., Tupyakova S.G.
Information about authors:
  • Neymark B.A. – Dr. Sci., Professor of the Department of Urology and Andrology with the course of additional postgraduate education of the «Altai State Medical University» of the Ministry of Health of the Russia; Barnaul, Russia; RSCI Author ID 78868442, https://orcid.org/0000-0001-8009-3777
  • Nashivochnikova N.A. – PhD, Associate Professor of the Department of Urology named after E.V. Shakhov of Privolzhsky Research Medical University Ministry of Health of Russia; Nizhny Novgorod, Russia; RSCI Author ID 980736, https://orcid.org/0000-0002-1138-1174
  • Smernitsky A.M. – Urologist, Russian Railways Medicine; Moscow, Russia; https://orcid.org/0000-0001-5084-6870
  • Melnik M.A. – PhD, Associate Professor of the Department of Urology and Andrology with the course of additional postgraduate education of the «Altai State Medical University» of the Ministry of Health of the Russia; Barnaul, Russia; RSCI Author ID 35864891, https://orcid.org/0000-0002-2405-0315
  • Tupyakova S.G. – student of Medical Department of the «Altai State Medical University» of the Ministry of Health of the Russian Federation; Barnaul, Russia; RSCI Author ID 1247735, https://orcid.org/0009-0007-0763-8014
95

Introduction. Urolithiasis is a widespread disease. The percentage of phosphate stones reaches up to 35% of all cases of all kidney stones. Patients with phosphate stones and with various urinary catheters in particular are a complex category of patients requiring the close attention of doctors. Phosphate urolithiasis clinical patterns create a constant search for various oral therapy options.

The purpose of this study is to evaluate the effectiveness of the Phosphalit complex as an optional drug for metabolic disorder correction in phosphate kidney stones.

Materials and methods. The prospective randomized control study included 135 patients, 131 people returned for a second visit. All the patients were divided in 4 groups: patients with phosphate urolithiasis who received Phosphalit® on a regular basis, 2 capsules 2 times a day; patients with phosphate urolithiasis who received general recommendations for lifestyle and diet changes; patients with phosphate urolithiasis against the back- ground of existing permanent urinary catheters, receiving the drug Phosphalit® on a regular basis, 2 capsules 2 times a day; patients with phosphate urolithiasis on the background of permanent urinary catheters, who received general recommendations for lifestyle and diet changes. The duration of observation and intervention was 90 days.

Results. The total effectiveness of Phosphalit® in reducing the level of phosphates in the blood in both groups of patients (with and without catheters) was 90.1%, and in reducing the excretion of phosphates in urine – 93.3%. The dynamics of the degree of crystalluria and the stone size also showed positive dynamics in all the studied groups.

Conclusions. Phosphalit® is an effective and safe remedy in the treatment of the phosphate urolithiasis, including patients with urinary catheters.

AttachmentSize
Download2.37 MB
urolithiasis; phosphate urolithia; metabolic disorders; bergenin; cranberry; niacinamide

Readera - Социальная платформа публикаций

Crossref makes research outputs easy to find, cite, link, and assess